PriceTargets.com logo

Hansa Biopharma AB (publ) - HNSBF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.83 As of 12/20/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for HNSBF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hansa Biopharma AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HNSBF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HNSBF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Hansa Biopharma AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.83.

This chart shows the closing price for HNSBF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Hansa Biopharma AB (publ). This rating has held steady since September 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/5/2022Bryan, Garnier & CoInitiated CoverageBuySEK 135
7/20/2022HC WainwrightBoost TargetBuy ➝ BuySEK 223 ➝ SEK 244
2/4/2022HC WainwrightLower TargetSEK 250 ➝ SEK 217
10/13/2021Royal Bank of CanadaReiterated RatingOutperform
6/23/2021HC WainwrightInitiated CoverageBuy
6/1/2021Royal Bank of CanadaReiterated RatingOutperform
4/26/2021DanskeInitiated CoverageBuy
7/7/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Hansa Biopharma AB (publ) logo
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Read More

Today's Range

Now: $2.83
Low: $2.83
High: $2.83

50 Day Range

MA: $3.34
Low: $2.83
High: $3.65

52 Week Range

Now: $2.83
Low: $2.83
High: $3.65

Volume

N/A

Average Volume

2,450 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hansa Biopharma AB (publ)?

The following Wall Street analysts have issued research reports on Hansa Biopharma AB (publ) in the last twelve months:
View the latest analyst ratings for HNSBF.

What is the current price target for Hansa Biopharma AB (publ)?

0 Wall Street analysts have set twelve-month price targets for Hansa Biopharma AB (publ) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hansa Biopharma AB (publ) in the next year.
View the latest price targets for HNSBF.

What is the current consensus analyst rating for Hansa Biopharma AB (publ)?

Hansa Biopharma AB (publ) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HNSBF.

What other companies compete with Hansa Biopharma AB (publ)?

Other companies that are similar to Hansa Biopharma AB (publ) include 180 Life Sciences, 3SBio, 60 Degrees Pharmaceuticals, Abcam and Adocia. Learn More about companies similar to Hansa Biopharma AB (publ).

How do I contact Hansa Biopharma AB (publ)'s investor relations team?

Hansa Biopharma AB (publ)'s physical mailing address is Scheelevägen 22, Lund, Skane 223. The company's listed phone number is 46 46 16 56 70. The official website for Hansa Biopharma AB (publ) is www.hansabiopharma.com. Learn More about contacing Hansa Biopharma AB (publ) investor relations.